Literature DB >> 14988225

High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria.

Jin Fu Wen1, Xun Cui, Jing Yu Jin, Soo Mi Kim, Sung Zoo Kim, Suhn Hee Kim, Ho Sub Lee, Kyung Woo Cho.   

Abstract

This study tests the hypothesis that particulate (p) guanylyl cyclase (GC) and soluble (s) GC are involved in the distinct roles for the regulation of cGMP-PDE-cAMP signaling and of mechanical and secretory functions in the heart. Experiments were performed in perfused beating rabbit atria. C-type natriuretic peptide (CNP) and SIN-1, an NO donor, or BAY 41-2272 (BAY), a direct activator for sGC, were used to activate pGC and sGC, respectively. CNP and SIN-1 increased cGMP and cAMP efflux in a concentration-dependent manner. Increase in cAMP was a function of cGMP. The changes in cAMP efflux concentration in terms of cGMP were much more prominent in the atria treated with CNP than in the atria treated with SIN-1. Increase in cAMP efflux concentration was blocked by milrinone but not changed by EHNA. BAY increased cGMP but not cAMP in a concentration-dependent manner. CNP and SIN-1 decreased atrial stroke volume and myocytic ANP release. The decreases in terms of cGMP efflux concentration were much more prominent in the atria treated with CNP than in the atria treated with SIN-1 or BAY. Milrinone accentuated GC agonist-induced decreases in atrial stroke volume and ANP release. In the presence of ODQ, SIN-1 or BAY induced effects were not observed. These data suggest that pGC and sGC activations have distinct roles via cGMP-PDE3-cAMP signaling in the cardiac atrium: high and low gain switches, respectively, for the regulation of cAMP levels and contractile and secretory functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988225     DOI: 10.1161/01.RES.0000123826.70125.4D

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  14 in total

1.  An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition.

Authors:  Noel Yan-Ki Chan; Nahid Seyedi; Kenichi Takano; Roberto Levi
Journal:  Circulation       Date:  2011-12-09       Impact factor: 29.690

2.  Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice.

Authors:  Yueh-Chen Lin; Roger H Adamson; Joyce F Clark; Rolf K Reed; Fitz-Roy E Curry
Journal:  J Physiol       Date:  2011-11-14       Impact factor: 5.182

3.  Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.

Authors:  Liliana R V Castro; Ignacio Verde; Dermot M F Cooper; Rodolphe Fischmeister
Journal:  Circulation       Date:  2006-05-01       Impact factor: 29.690

4.  Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.

Authors:  Natalia N Mendelev; Verietta S Williams; David A Tulis
Journal:  J Cardiovasc Pharmacol       Date:  2009-02       Impact factor: 3.105

5.  Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice.

Authors:  Eric P Schmidt; Mahendra Damarla; Otgonchimeg Rentsendorj; Laura E Servinsky; Bing Zhu; Aigul Moldobaeva; Alfredo Gonzalez; Paul M Hassoun; David B Pearse
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-10       Impact factor: 5.464

Review 6.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

7.  Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle.

Authors:  Faraz Afzal; Eirik Qvigstad; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-08       Impact factor: 3.000

8.  CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.

Authors:  Yang Chen; Gail J Harty; Brenda K Huntley; Seethalakshmi R Iyer; Denise M Heublein; Gerald E Harders; Laura Meems; Shuchong Pan; S Jeson Sangaralingham; Tomoko Ichiki; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-29       Impact factor: 3.210

9.  CNP-pGC-cGMP-PDE3-cAMP Signal Pathway Upregulated in Gastric Smooth Muscle of Diabetic Rats.

Authors:  Ying-Lan Cai; Mo-Han Zhang; Xu Huang; Jing-Zhi Jiang; Li-Hua Piao; Zheng Jin; Wen-Xie Xu
Journal:  Gastroenterol Res Pract       Date:  2015-03-25       Impact factor: 2.260

10.  M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.

Authors:  Paul M McKie; Alessandro Cataliotti; Tomoko Ichiki; S Jeson Sangaralingham; Horng H Chen; John C Burnett
Journal:  J Am Heart Assoc       Date:  2014-01-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.